Boehringer Ingelheim Gains CHMP Positive Opinion for Nerandomilast in IPF and PPF

Boehringer Ingelheim's nerandomilast (JASCAYD®) has cleared a critical EU regulatory checkpoint, with the Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for its use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). A European Commission decision, which typically follows within two months of a CHMP recommendation, would extend the compound's approved footprint to a fifth major market.

The opinion rests on data from the Phase III FIBRONEER™ programme, which evaluated efficacy and safety across both IPF and PPF patient populations. Nerandomilast is a preferential PDE4B inhibitor and, if EC approval follows, will enter the EU as the first new IPF therapy in over a decade. Regulatory affairs leads tracking the EU dossier should note that the CHMP recommendation consolidates a multi-regional approval sequence already covering the US, China, UAE, and Japan.

For QA directors and supply-chain leads at Boehringer Ingelheim's manufacturing sites, a positive EC decision triggers the obligation to align commercial batch release procedures with EU GMP and 21 CFR Part 211-equivalent expectations under the mutual recognition framework. Process validation documentation and sterility assurance protocols established for existing markets will require review against EMA-specific requirements before first EU commercial release.

IPF and PPF are progressive, life-threatening fibrotic lung diseases that demand early and sustained pharmacological intervention. The dual indication scope of the CHMP opinion broadens the addressable patient population relative to single-indication fibrosis treatments, a factor that will shape demand forecasting and capacity planning across fill-finish and secondary packaging operations.

The European Commission's formal marketing authorisation decision will set the definitive timeline for EU commercial launch and the activation of post-approval commitments outlined in the risk management plan.

Source: Boehringer Ingelheim via GlobeNewswire, 22 May 2026.